REG - Cambridge Cognition - Result of AGM

Cambridge Cognition HoldingsAnnouncement

Yesterday 15:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260521:nRSU3339Fa&default-theme=true

RNS Number : 3339F  Cambridge Cognition Holdings PLC  21 May 2026

21 May 2026

 

Cambridge Cognition Holdings plc

("Cambridge Cognition" or the "Company")

 

Result of AGM

 

Cambridge Cognition Holdings plc (AIM: COG), the neuroscience technology
company whose digital cognitive assessments drive scientific discovery,
accelerate drug development and improve patient care, held its Annual General
Meeting ("AGM") earlier today at the registered office of the Company;
Tunbridge Court, Tunbridge Lane, Bottisham, Cambridge, CB25 9TU and announces
that all resolutions put forward were duly passed.

 

Proxy votes were received in respect of 59.3% of the Company's issued share
capital. The votes cast were as follows:

 

     Resolution                                                    Votes For   Percent of votes cast For  Votes Against  Percent of votes cast Against  Votes Withheld
 1   To approve the 2025 Report and Accounts                       27,607,286  100%                       -              -                              22,265
 2   To approve the 2025 Directors' Remuneration Report(1)         27,576,829  99.83%                     47,714         0.17%                          5,008
 3   To appoint the auditors                                       27,595,679  99.92%                     22,660         0.08%                          11,212
 4   To authorise the Directors to set the auditors' remuneration  27,602,281  99.99%                     2              0.01%                          27,268
 5   To re-elect Stuart Gall as a Director                         27,602,093  99.92%                     22,440         0.08%                          5,018
 6   To re-elect Jon Kempster as a Director                        27,601,693  99.92%                     22,840         0.08%                          5,018
 7   To re-elect Nick Rodgers as a Director                        27,601,693  99.92%                     22,840         0.08%                          5,018
 8   To elect Rob Baker as a Director                              27,602,273  99.92%                     22,260         0.08%                          5,018
 9   To elect Ronald Openshaw as a Director                        27,602,273  99.92%                     22,260         0.08%                          5,018
 10  Authority to allot shares                                     27,572,233  99.79%                     57,313         0.21%                          5
 11  Authority to disapply pre-emption rights(2)                   27,569,635  99.80%                     54,898         0.20%                          5,018
 12  Authority to purchase own shares on the market(2)             24,196,722  99.90%                     25,412         0.10%                          3,407,417

 

 

Notes

1. Indicates an advisory vote.

2. Indicates a Special Resolution requiring 75% of votes cast to be carried.

 

Enquiries:

 

 Cambridge Cognition Holdings plc                            Tel: 01223 810700

 Rob Baker, Chief Executive Officer                          press@camcog.com (mailto:press@camcog.com)

 Ronald Openshaw, Chief Financial Officer

 Cavendish Capital Markets Limited (NOMAD and Joint Broker)  Tel: 020 7220 0500

 Geoff Nash / Elysia Bough / Joe Smith                       Corporate Finance

 Harriet Ward                                                Corporate Broking

 Nigel Birks                                                 LS Specialist Sales

 Singer Capital Markets Limited (Joint Broker)               Tel: 020 7496 3000

 Amber Higgs / James Serjeant / Daniel Ingram

 

Notes to Editors

 

About Cambridge Cognition

 

Cambridge Cognition is a neuroscience technology company whose digital
cognitive assessments drive scientific discovery, accelerate drug development
and improve patient care.

 

Built on rich, curated data and deep technical expertise we are building a
strong global brand with scalable technology that will support the rising
world demand for diagnosing and treating brain health. The Company creates
shareholder value through organic sales growth, strategic partnerships, joint
ventures, and spinouts. The Company has identified four market sectors:

 

·      Clinical Studies for new pharmaceuticals;

·      Academic Research for scientists to understand CNS disorders;

·      Healthcare to provide physicians with cognitive assessments to
allow them to diagnose and treat patients; and,

·      Consumer Health & Wellness to provide individuals access to
accurate, reliable, and meaningful data to assess their cognitive health.

 

For further information, visit: www.cambridgecognition.com
(http://www.cambridgecognition.com) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGAKDBQNBKDNPB



            Copyright 2019 Regulatory News Service, all rights reserved